Lexaria Bioscience Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Lexaria Bioscience heeft een totaal eigen vermogen van $9.7M en een totale schuld van $0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk $10.0M en $271.4K.

Belangrijke informatie

Verhouding schuld/eigen vermogen

US$0

Schuld

Rente dekkingsratio	n/a
Contant	US$8.51m
Aandelen	US$9.75m
Totaal verplichtingen	US$271.38k
Totaal activa	US$10.02m

Recente financiële gezondheidsupdates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $9.1M ) LEXX } overtreffen de korte termijn passiva ( $156.0K ).

Langlopende schulden: De kortetermijnactiva LEXX ( $9.1M ) overtreffen de langetermijnschulden ( $115.3K ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: LEXX is schuldenvrij.

Schuld verminderen: LEXX had 5 jaar geleden geen schulden.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: LEXX heeft op basis van de huidige vrije kasstroom voldoende kasstroom voor meer dan een jaar.

Voorspelling contante baan: LEXX heeft voldoende kasruimte voor 1.7 jaar als de vrije kasstroom blijft dalen met een historisch percentage van 13.8 % per jaar.

Lexaria Bioscience Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Lexaria Bioscience Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)

Lexaria Bioscience Receives Nasdaq Bid Price Deficiency Notice

Recent updates

Lexaria Bioscience Corp. Receives Final 12-Week Body Weight and Blood Sugar Results from All 12 Study Groups of the Recently Completed Diabetes Animal Study

Lexaria Bioscience Corp., Annual General Meeting, Jan 14, 2025

Lexaria Bioscience Corp. Announces Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Lexaria Bioscience Corp. Receives Partial 12-Week Body Weight Results from the Recently Completed Animal Study WEIGHT-A24-1

Lexaria Bioscience Corp. has completed a Follow-on Equity Offering in the amount of $5 million.

Lexaria Bioscience Corp. has filed a Follow-on Equity Offering in the amount of $5 million.

Lexaria Bioscience Corp. has filed a Follow-on Equity Offering in the amount of $5 million.

Lexaria Bioscience Begins Dosing in Human Pilot Study for Oral Tirzepatide Using Dehydratech Technology

Lexaria Bioscience Corp. Appoints Michael Shankman as Chief Financial Officer

Lexaria Bioscience Corp Receives Independent Review Board Approval to Begin Human Pilot Study #3

Lexaria Bioscience Corp. Announces Chief Executive Officer Changes

Lexaria Bioscience Corp. Announces Second GLP-1 Human Pilot Study Shows Zero Adverse Events in Dehydratech-Processed Rybelsus Oral Capsules

First Results from Lexaria's Second GLP-1 Human Pilot Study

Lexaria Bioscience Corp. Announces Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

Lexaria Bioscience Corp. Receives 4-Week and 8-Week Blood Sugar Results from Ongoing Animal Study WEIGHT-A24-1

Lexaria Bioscience Corp. Announces Positive Results from Lexaria's Molecular Characterization Study

Consensus revenue estimates fall by 24%

Lexaria Bioscience Corp. Announces Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Lexaria Bioscience Corp. Completes Human Pilot Study 2, GLP-1- H2 4-2

Lexaria Bioscience Corp. Announces Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study

Lexaria Bioscience Corp. Announces Dosing Begins in Comprehensive GLP-1 Animal Study

Lexaria Bioscience Corp. Begins Dosing of Its Second Glp-1 Human Pilot Study

Consensus revenue estimates increase by 24%

Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study

Second quarter 2024 earnings released: US$0.06 loss per share (vs US$0.22 loss in 2Q 2023)

Lexaria Appoints Nelson Cabatuan as Chief Financial Officer

Lexaria Bioscience Corp., Annual General Meeting, Apr 23, 2024

Lexaria to Begin Diabetes and Weight Loss Animal Study Well-A24-1

Lexaria Bioscience Corp. Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial

Lexaria Bioscience Corp. has completed a Follow-on Equity Offering in the amount of $3.599992 million.

Lexaria Bioscience Corp. has filed a Follow-on Equity Offering in the amount of $3.599992 million.

Lexaria Bioscience Corp. Submits Investigational New Drug Application

Consensus revenue estimates increase by 100%

Lexaria Bioscience Corp. Unveils Extensive Planned 2024 GLP-1 Study Program

First quarter 2024 earnings released: US$0.13 loss per share (vs US$0.29 loss in 1Q 2023)

Lexaria Bioscience Corp. Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream

Lexaria Bioscience Corp. Improves Delivery, Efficacy of Glp-1 Agonists Through Proprietary Drug-Delivery Platform

Lexaria Bioscience Corp. Announces Positive Final Results from its Recently Completed Human Pilot Study #1 for the Oral Performance of the Rybelsus(R)-Branded GLP-1 Drug Semaglutide

Lexaria Bioscience Corp. Announces Investigational New Drug Application Filing Update

Consensus revenue estimates decrease by 20%, EPS upgraded

Lexaria's Technology Improves the Oral Performance of the Rybelsus(R-Branded GLP-1 Drug Semaglutide in Human Pilot Study

Lexaria's Technology Improves the Oral Performance of the Rybelsus(R-Branded GLP-1 Drug Semaglutide in Human Pilot Study

Full year 2023 earnings: EPS and revenues miss analyst expectations

Lexaria Bioscience Corp. has completed a Follow-on Equity Offering in the amount of $0.114546 million.

Lexaria Bioscience Corp. Evaluates Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs

Lexaria Bioscience Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)

New major risk - Shareholder dilution

Lexaria Bioscience Corp. Announces Its Intention to Launch New Human and Animal Studies to Examine Dehydratech™-Processed Glucagon-Like Peptide-1

Lexaria Bioscience Corp. Provides Update on Investigational New Drug Application Progress

Consensus revenue estimates increase by 38%, EPS downgraded

Lexaria Bioscience Corp.'s DehydraTECH-Nicotine Faster than ZYN and on

Lexaria Bioscience Corp.'s DehydraTECH-Nicotine Faster than ZYN and on

Lexaria Bioscience Corp Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD

Lexaria Bioscience Corp Grants Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products

New major risk - Revenue and earnings growth

New major risk - Financial position

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Share price stability

Lexaria Bioscience Receives Nasdaq Bid Price Deficiency Notice

Lexaria's DehydraTECH-CBD Lowers Blood Glucose Levels in Diabetes Animal Study

Lexaria Bioscience Corp. Announces Chief Financial Officer Changes

Lexaria Bioscience Corp. Discovers That DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers

Lexaria Bioscience Corp. Hormone Study Shows Significant Enhancement in Oral Estradiol Delivery

Lexaria Bioscience Corp. Announces Batch Manufacturing of the DehydraTECH™-Processed Cannabidiol

Lexaria Bioscience Corp. has completed a Composite Units Offering in the amount of $2.0007 million.

Lexaria Bioscience Corp. has completed a Composite Units Offering.

Lexaria Bioscience Corp. Human Clinical Nicotine Study Completes Dosing as Planned

Consensus revenue estimates fall by 65%

Second quarter 2023 earnings released: US$0.22 loss per share (vs US$0.24 loss in 2Q 2022)

Lexaria Bioscience Corp. Appoints Julian Gangolli as Strategic Advisor

First quarter 2023 earnings released: US$0.29 loss per share (vs US$0.35 loss in 1Q 2022)

Lexaria Bioscience Corp.'s DehydraTECH-CBD Achieves Superior Human Blood Absorption Levels